Results 21 to 30 of about 8,358 (142)

Comparison of the Effects of Zonisamide and Flupirtine on Paclitaxel Induced Peripheral Neuropathy in Rats [PDF]

Journal of Clinical and Diagnostic Research, 2018
Introduction: Many peripheral and central causes lead to neuropathic pain disorders. Effective treatment of neuropathic pain is not completely manageable and hence, it becomes necessary to evaluate the application of Zonisamide as a sodium channel and T ...
Bhuvaneswari Krishnamurthy, Prashanth Ashok Kumar, Abilash Sathyanarayanan   +2 more
doaj   +1 more source

Quantification of Zonisamide in Dried Blood Spots and Dried Plasma Spots by UPLC–MS/MS: Application to Clinical Practice

Molecules, 2022
In this research, a UHPLC–MS/MS method was developed and validated for the determination of zonisamide in dried plasma spots (DPS) and dried blood spots (DBS).
Milena Rmandić, Ana Stajić, Jasna Jančić, Janko Samardžić, Nebojša Jović, Anđelija Malenović   +5 more
doaj   +1 more source

Zonisamide for the Treatment of Parkinson Disease: A Current Update

Frontiers in Neuroscience, 2020
Zonisamide has been used as an add-on treatment in order to overcome the deficiencies of the general therapies currently used to resolve the motor complications and non-motor symptoms of Parkinson disease. Various trials have been designed to investigate
Chengqian Li, Li Xue, Yumei Liu, Zhengjie Yang, Song Chi, Anmu Xie   +5 more
doaj   +1 more source

Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

Cells, 2018
Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear.
Shin-Ichi Ueno, Shinji Saiki, Motoki Fujimaki, Haruka Takeshige-Amano, Taku Hatano, Genko Oyama, Kei-Ichi Ishikawa, Akihiro Yamaguchi, Shuko Nojiri, Wado Akamatsu, Nobutaka Hattori   +10 more
doaj   +1 more source

Review: A review of the use of zonisamide in Parkinson’s disease

Therapeutic Advances in Neurological Disorders, 2009
Although zonisamide was previously only used to treat epilepsy, recently more applications have been forthcoming. Due to a good side effect profile, a lower frequency of interactions and a more comfortable posology, there are several studies regarding ...
Pedro Emilio Bermejo, Buenaventura Anciones   +1 more
doaj   +1 more source

Neuroinflammation following anti-parkinsonian drugs in early Parkinson’s disease: a longitudinal PET study

Scientific Reports
The progression of neuroinflammation after anti-parkinsonian therapy on the Parkinson’s disease (PD) brain and in vivo evidence of the therapy purporting neuroprotection remain unclear.
Tatsuhiro Terada, Tomoyasu Bunai, Takanori Hashizume, Takashi Matsudaira, Masamichi Yokokura, Hirotsugu Takashima, Takashi Konishi, Tomokazu Obi, Yasuomi Ouchi   +8 more
doaj   +1 more source

Third generation antiepileptic drugs: mechanism of action, pharmacokinetics, interaction and use in childhood

Эпилепсия и пароксизмальные состояния, 2023
The review considers pharmacological characteristics of new antiepileptic drugs (AEDs) of the third generation such as eslicarbazepine, lacosamide, retigabine, perampanel, everolimus, brivaracetam, zonisamide.
Z. G. Tadtaeva, A. N. Galustyan, O. A. Gromova, I. S. Sardaryan   +3 more
doaj   +1 more source

Zonisamide

Reactions Weekly
Kadian R, Patel P, Kumar A.
europepmc   +2 more sources

Bioequivalence of Different Formulations of Zonisamide Oral Suspensions: A Short Review

Patient Preference and Adherence, 2023
Ivana Stević,1 Nemanja Petrović,2 Slobodan M Janković2 1Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia; 2Faculty of Medical Sciences, University of Kragujevac, Kragujevac, SerbiaCorrespondence: Slobodan M Jankovi ...
Stević I, Petrović N, Janković SM
doaj  

Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs

Health Technology Assessment, 2021
Background: Levetiracetam (Keppra®, UCB Pharma Ltd, Slough, UK) and zonisamide (Zonegran®, Eisai Co. Ltd, Tokyo, Japan) are licensed as monotherapy for focal epilepsy, and levetiracetam is increasingly used as a first-line treatment for generalised ...
Anthony G Marson, Girvan Burnside, Richard Appleton, Dave Smith, John Paul Leach, Graeme Sills, Catrin Tudur-Smith, Catrin O Plumpton, Dyfrig A Hughes, Paula R Williamson, Gus Baker, Silviya Balabanova, Claire Taylor, Richard Brown, Dan Hindley, Stephen Howell, Melissa Maguire, Rajiv Mohanraj, Philip EM Smith   +18 more
doaj   +1 more source